Background and purpose:Radiotherapy is the common method for treatment of prostate carcinoma,but some patients cannot tolerate the side effects caused by conventional pelvic radiation.MRI can display clearly the disease in the prostate and surrounding tissue.Modified pelvic radiation directed by MRI staging system can reduce the adverse reaction.This study was to evaluate the value of Magnetic Resonance Imaging(MRI) Staging(TNM staging system) in radiotherapy of prostate carcinoma.Methods:From 1998 to 2003 Sixty-three patients with prostate carcinoma who were confirmed as stage T_(1-2)N_(0)M_(0) by MRI staging system were randomly allocated into two arms: 29 patients in arm A were treated with conventional pelvic radiation(D_(T)4000-4500cGy),and 34 patients in arm B received modified pelvic radiation(D_(T)4000-4500cGy),then 2500-3000cGy were added by conformal radiation therapy.Results:After median follow-up of 61 months,the median survival time was 82 months for conventional pelvic radiation group compared with 76.3 months for modified pelvic radiation group(P=0.673);5-year overall survival rates were 83.97% and 79.64% for conventional pelvic radiation group and modified pelvic radiation group,respectively.The median PSA failure-free survival time for two arms was similar,59 month(conventional pelvic radiation group) versus 60 months(modified pelvic radiation group)(P=(0.859));5-year PSA failure-free survival rates were 42.37% for conventional pelvic radiation group and 49.01% for modified pelvic radiation group,respectively.The morbidity such as acute/chronic gastrointestinal and genitourinary side effects were higher in conventional pelvic radiation group than in modified pelvic radiation group.Conclusions:The local control rates and survival rates for patients with staging T_(1-2)N_(0)M_(0) prostate carcinoma who received modified radiotherapy or conventional radiotherapy were similar,but the toxicities of modified radiotherapy were significantly less than that of conventional radiotherapy.

Objective To evaluate the dosimetric differences of one RapidPlan Model on different Radiotherapy devices.Methods A RapidPlan Model was built based on 30 reoptimization IMRT plans of cervical cancer patients on typeA LA.Dosimetric differences of automatic optimized IMRT plans using this model on 4 different type LAs,named respectivelyA,B,C andD,were compared with 12 test cervical cancer cases.These four LAs were well commissioned in the treatment planning system (TPS).Student t test was applied for statistical analysis on dosimetric differences.Results Dosimetric differences between A vs.B,C and D were observed on Dmean,HI,CI of PTV50 and PTV45,as well as on V50,V40,V30 of rectum and bladder.Significant dosimetric differences were observed between A and D (P<0.05).Conclusions Automatic planning with RapidPlan model may result in dosimetric differences on different Radiotherapy devices.These differences should be aware of with caution in its clinical application.

To investigate the effect of RAD18-siRNA on cell proliferation and chemotherapy sensitivity of esophageal squamous cell carcinoma (ESCC) ECA-109 cells.RAD18-siRNA was transfected into human ECA-109 cells by Lipofectamine 3000. Quantitative PCR and Western blot were performed to detect RAD18 and CyclinD1 expression; CCK-8 assay was used to determine cell proliferation and chemotherapy drug sensitivity; flow cytometry was used to determine cell cycle. Correlation between RAD18 and CyclinD1 mRNA expression was analyzed by Pearson's correlation.Compared with non-transfected cells, the expression of RAD18 in RAD18-siRNA group was significantly decreased (<0.05). The cell proliferation was inhibited (<0.05) and the cell number of G1 phase was increased, G2/M phase cells decreased (<0.05) in RAD18-siRNA group. After treatment with different concentrations of cisplatin or 5-FU, the survival rate of the two cell groups was reduced (all<0.05), and the IC50 of RAD18-siRNA group was significantly lower than that of non-transfected group (<0.05). The mRNA expression of RAD18 was positively correlated with CyclinD1 expression in ESCC tissues(=0.478,<0.01).Down-regulated expression of RAD18 can decrease the cell proliferation and increase chemo-sensitivity of ESCC cells, and CyclinD1 may participate in the process.
Adjuvants, Pharmaceutic ; pharmacology ; Carcinoma, Squamous Cell ; drug therapy ; physiopathology ; Cell Cycle ; Cell Line, Tumor ; Cell Proliferation ; drug effects ; Cisplatin ; pharmacology ; Cyclin D1 ; drug effects ; genetics ; DNA-Binding Proteins ; administration & dosage ; pharmacology ; Down-Regulation ; drug effects ; genetics ; Drug Resistance, Neoplasm ; drug effects ; Drug Screening Assays, Antitumor ; methods ; Drug Synergism ; Esophageal Neoplasms ; drug therapy ; physiopathology ; Fluorouracil ; pharmacology ; G1 Phase ; drug effects ; G2 Phase ; drug effects ; Humans ; Metaphase ; drug effects ; RNA, Small Interfering ; administration & dosage ; pharmacology ; Transfection ; Ubiquitin-Protein Ligases ; administration & dosage ; pharmacology